NEXI Insider Trading
Insider Ownership Percentage: 14.90%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00
NexImmune Share Price & Price History
Current Price: $0.00
Price Change: ▼ Price Decrease of -0.0099 (-99.00%)
As of 12/18/2025 12:49 PM ET
NexImmune Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 6/11/2024 | Kristi Jones | CEO | Buy | 1 | $0.01 | $0.01 | 1 |  |
| 11/21/2023 | Alan S Roemer | Director | Sell | 3,833 | $2.16 | $8,279.28 | 3,992 | |
| 3/30/2023 | Sol J Barer | Director | Buy | 16,000 | $10.25 | $164,000.00 | 88,712 | |
NexImmune Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 3/22/2024 | PNC Financial Services Group Inc. | 12,640 | $28K | 0.0% | -96.0% | 1.192% |  |
| 5/16/2023 | Slate Path Capital LP | 925,000 | $0.35M | 0.0% | N/A | 3.547% | |
| 4/26/2023 | Caprock Group LLC | 103,482 | $39K | 0.0% | +82.9% | 0.397% | |
| 4/14/2023 | Raymond James & Associates | 320,622 | $0.12M | 0.0% | +947.0% | 1.229% | |
| 11/15/2022 | First Manhattan Co. | 66,214 | $36K | 0.0% | -27.4% | 0.274% | |
| 8/15/2022 | Kettle Hill Capital Management LLC | 272,447 | $0.44M | 0.1% | N/A | 1.193% | |
| 7/27/2022 | Bailard Inc. | 20,285 | $33K | 0.0% | N/A | 0.089% | |
| 5/10/2022 | Smith Salley & Associates | 11,000 | $46K | 0.0% | N/A | 0.048% | |
| 4/12/2022 | CAPROCK Group Inc. | 56,582 | $0.24M | 0.0% | N/A | 0.248% | |
| 2/11/2022 | M28 Capital Management LP | 133,442 | $0.62M | 0.5% | N/A | 0.588% | |
| 2/9/2022 | First Republic Investment Management Inc. | 100,000 | $0.46M | 0.0% | N/A | 0.440% | |
| 2/4/2022 | TimesSquare Capital Management LLC | 216,391 | $1M | 0.0% | -52.4% | 0.953% | |
| 2/2/2022 | New York State Common Retirement Fund | 9,259 | $43K | 0.0% | +60.5% | 0.041% | |
| 11/17/2021 | ArrowMark Colorado Holdings LLC | 1,958,813 | $29.66M | 0.2% | -23.1% | 8.625% | |
| 11/16/2021 | Suvretta Capital Management LLC | 344,223 | $5.21M | 0.1% | -5.9% | 1.521% | |
| 11/16/2021 | Metropolitan Life Insurance Co NY | 5,828 | $88K | 0.0% | N/A | 0.026% | |
| 11/15/2021 | 683 Capital Management LLC | 100,687 | $1.52M | 0.1% | +67.8% | 0.445% | |
| 11/15/2021 | Kingdon Capital Management L.L.C. | 117,962 | $1.79M | 0.2% | N/A | 0.521% | |
| 11/15/2021 | First Manhattan Co. | 147,159 | $2.23M | 0.0% | N/A | 0.650% | |
| 11/12/2021 | Rockefeller Capital Management L.P. | 27,860 | $0.42M | 0.0% | N/A | 0.123% | |
| 11/12/2021 | The Manufacturers Life Insurance Company | 10,464 | $0.16M | 0.0% | N/A | 0.046% | |
| 11/12/2021 | Geode Capital Management LLC | 212,431 | $3.22M | 0.0% | +87.4% | 0.939% | |
| 11/12/2021 | Edgewood Management LLC | 56,015 | $0.85M | 0.0% | N/A | 0.248% | |
| 11/10/2021 | Citigroup Inc. | 3,335 | $50K | 0.0% | +935.7% | 0.015% | |
| 11/9/2021 | BlackRock Inc. | 812,664 | $12.30M | 0.0% | +150.4% | 3.591% | |
| 11/8/2021 | TimesSquare Capital Management LLC | 454,550 | $6.88M | 0.1% | -5.7% | 2.009% | |
| 11/4/2021 | Deutsche Bank AG | 10,149 | $0.15M | 0.0% | +159.6% | 0.045% | |
| 11/2/2021 | Raymond James & Associates | 25,957 | $0.39M | 0.0% | N/A | 0.115% | |
| 11/1/2021 | SG Americas Securities LLC | 7,524 | $0.11M | 0.0% | N/A | 0.033% | |
Data available starting January 2016
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It provides NEXI-004 which is in preclinical stage for EBV related diseases; and NEXI005 designs for patient with specific targets for solid tumors. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.
Read More on NexImmune
Volume
9,088 shs
Average Volume
4,327 shs
Market Capitalization
$139.50
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.98
Who are the company insiders with the largest holdings of NexImmune?
